FDA 356h Application to Market a New Drug, Biologic, or an Antibi

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE (Title 21, Code of Federal Regulations, Parts 314 & 601)

Form Approved: OMB No. 0910-0338 Expiration Date: August 31, 2005 See OMB Statement on page 2.

FOR FDA USE ONLY

APPLICATION NUMBER

     

APPLICANT INFORMATION

NAME OF APPLICANT

DATE OF SUBMISSION

     

     

TELEPHONE NO. (Include Area Code)

FACSIMILE (FAX) Number (Include Area Code)

     

     

APPLICANT ADDRESS (Number, Street, City, State, Country, ZIP Code or Mail Code, and U.S. License number if previously issued):

AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, ZIP Code, telephone & FAX number) IF APPLICABLE

     

     

PRODUCT DESCRIPTION

NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENSE APPLICATION NUMBER (If previously issued)      

ESTABLISHED NAME (e.g., Proper name, USP/USAN name)

PROPRIETARY NAME (trade name) IF ANY

     

     

CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (If any)

CODE NAME (If any)

     

     

DOSAGE FORM:

STRENGTHS:

ROUTE OF ADMINISTRATION:

     

     

     

(PROPOSED) INDICATION(S) FOR USE:

     

APPLICATION DESCRIPTION

APPLICATION TYPE (check one) NEW DRUG APPLICATION (CDA, 21 CFR 314.50) ABBREVIATED NEW DRUG APPLICATION (ANDA, 21 CFR 314.94) BIOLOGICS LICENSE APPLICATION (BLA, 21 CFR Part 601)

IF AN NDA, IDENTIFY THE APPROPRIATE TYPE 505 (b)(1) 505 (b)(2)

IF AN ANDA, OR 505(b)(2), IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION

Name of Drug

     

Holder of Approved Application

     

TYPE OF SUBMISSION (check one) ORIGINAL APPLICATION AMENDMENT TO APENDING APPLICATION RESUBMISSION PRESUBMISSION ANNUAL REPORT ESTABLISHMENT DESCRIPTION SUPPLEMENT EFFICACY SUPPLEMENT LABELING SUPPLEMENT CHEMISTRY MANUFACTURING AND CONTROLS SUPPLEMENT OTHER

IF A SUBMISSION OF PARTIAL APPLICATION, PROVIDE LETTER DATE OF AGREEMENT TO PARTIAL SUBMISSION:

     

IF A SUPPLEMENT, IDENTIFY THE APPROPRIATE CATEGORY CBE CBE-30 Prior Approval (PA)

REASON FOR SUBMISSION

     

PROPOSED MARKETING STATUS (check one) PRESCRIPTION PRODUCT (Rx) OVER THE COUNTER PRODUCT (OTC)

NUMBER OF VOLUMES SUBMITTED

     

THIS APPLICATION IS PAPER PAPER AND ELECTRONIC ELECTRONIC

ESTABLISHMENT INFORMATION (Full establishment information should be provided in the body of the Application.) Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.

     

Cross References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs, and DMFs referenced in the current application)

     

This application contains the following items: (Check all that apply)
	1. Index
	2. Labeling (check one) Draft Labeling Final Printed Labeling
	3. Summary (21 CFR 314.50 (c))
	4. Chemistry section
	A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)
	B. Samples (21 CFR 314.50 (e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA’s request)
	C. Methods validation package (e.g., 21 CFR 314.50(e)(2)(i); 21 CFR 601.2)
	5. Nonclinical pharmacology and toxicology section (e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2)
	6. Human pharmacokinetics and bioavailability section (e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)
	7. Clinical Microbiology (e.g., 21 CFR 314.50(d)(4))
	8. Clinical data section (e.g., 21 CFR 314.50(d)(5); 21 CFR 601.2)
	9. Safety update report (e.g., 21 CFR 314.50(d)(5)(vi)(b); 21 CFR 601.2)
	10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)
	11. Case report tabulations (e.g., 21 CFR 314.50(f)(1); 21 CFR 601.2)
	12. Case report forms (e.g., 21 CFR 314.50 (f)(2); 21 CFR 601.2)
	13. Patent information on any patent which claims the drug (21 U.S.C. 355(b) or (c))
	14. A patent certification with respect to any patent which claims the drug (21 U.S.C. 355 (b)(2) or (j)(2)(A))
	15. Establishment description (21 CFR Part 600, if applicable)
	16. Debarment certification (FD&C Act 306 (k)(1))
	17. Field copy certification (21 CFR 314.50 (l)(3))
	18. User Fee Cover Sheet (Form FDA 3397)
	19. Financial Information (21 CFR Part 54)
	20. OTHER (Specify)      
CERTIFICATION I agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications, warnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as requested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications, including, but not limited to the following: 1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 606, and/or 820. 2. Biological establishment standards in 21 CFR Part 600. 3. Labeling regulations in 21 CFR Parts 201, 606, 610, 660, and/or 809. 4. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR Part 202. 5. Regulations on making changes in application in FD&C Act section 506A, 21 CFR 314.71, 314.72, 314.97, 314.99, and 601.12. 6. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80, and 600.81. 7. Local, state and Federal environmental impact laws. If this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act, I agree not to market the product until the Drug Enforcement Administration makes a final scheduling decision. The data and information in this submission have been reviewed and, to the best of my knowledge are certified to be true and accurate. Warning: A willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.
SIGNATURE OF RESPONSIBLE OFFICIAL OR AGENT			TYPED NAME AND TITLE		DATE:
			     		     
ADDRESS (Street, City, State, and ZIP Code)				Telephone Number
     				(     )      
Public reporting burden for this collection of information is estimated to average 24 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:
Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Central Document Room 5901-B Ammendale Road Beltsville, MD 20705-1266		Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (HFM-99) 1401 Rockville Pike Rockville, MD 20852-1448		An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

INSTRUCTIONS FOR FILLING OUT FORM FDA 356h

APPLICANT INFORMATION This section should include the name, street address, telephone

and facsimile numbers of the legal person or entity submitting the application in the appropriate areas.

Note that, in the case of biological products, this is the name of the legal entity or person to whom the

license will be issued. The name, street address and telephone number of the legal person or entity

authorized to represent a non-U.S. applicant should be entered in the indicated area. Only one person

should sign the form.

PRODUCT DESCRIPTION This section should include all of the information necessary to identify

the product that is the subject of this submission. For new applications, the proposed indication

should be given. For supplements to an approved application, please give the approved indications for

use.

APPLICATION INFORMATION If this submission is an ANDA or 505(b)(2), this section should

include the name of the approved drug that is the basis of the application and identify the holder of

the approved application in the indicated areas.

TYPE OF SUBMISSION should be indicated by checking the appropriate box:

Original Application = a complete new application that has never before been submitted;

Amendment to a Pending Application = all submissions to pending original applications, or

pending supplements to approved applications, including responses to Information Request Letters;

Resubmission = a complete response to an action letter, or submission of an application that has been

the subject of a withdrawal or a refusal to file action;

Presubmission = information submitted prior to the submission of a complete new application;

Annual Report = periodic reports for licensed biological products (for NDAs Form FDA-2252

should be used as required in 21 CFR 314.81 (b)(2));

Establishment Description Supplement = supplements to the information contained in the

Establishment Description section (#15) for biological products;

Efficacy Supplement = submissions for such changes as a new indication or dosage regimen for an

approved product, a comparative efficacy claim naming another product, or a significant alteration in

the patient population; e.g., prescription to Over-The-Counter switch;

Labeling Supplement = all label change supplements required under 21 CFR 314.70 and 21 CFR

601.12 that do not qualify as efficacy supplements;

Chemistry, Manufacturing, and Controls Supplement = manufacturing change supplement

submissions as provided in 21 CFR 314.70, 21 CFR 314.71, 21 CFR 314.72 and 21 CFR 601.12;

Other = any submission that does not fit in one of the other categories (e.g., Phase IV response). If

this box is checked the type of submission can be explained in the REASON FOR SUBMISSION

block.

Submission of Partial Application Letter date of agreement to partial submission should be

provided. Also, provide copy of scheduled plan.

CBE "Supplement-Changes Being Effected" supplement submission for certain moderate changes for

which distribution can occur when FDA receives the supplement as provided in 21 CFR 314.70 and

21 CFR 601.12.

CBE-30 "Supplement-Changes Being Effected in 30 Days" supplement submission for certain

moderate changes for which FDA receives at least 30 days before the distribution of the product made

using the change as provided in 21 CFR 314.70 and 21 CFR 601.12.

Prior Approval (PA) "Prior Approval Supplements" supplement submission for a major change for

which distribution of the product made using the change cannot occur prior to FDA approval as

provided in 21 CFR 314.70 and 21 CFR 601.12.

REASON FOR SUBMISSION This section should contain a brief explanation of the submission,

e.g., "manufacturing change from roller bottle to cell factory" or "response to Information Request

Letter of 1/9/97" or "Pediatric exclusivity determination request" or "to satisfy a subpart H

postmarketing commitment".

NUMBER OF VOLUMES SUBMITTED Please enter the number of volumes, including and

identifying electronic media, contained in the archival copy of this submission.

This application is

Paper Paper and Electronic Electronic

Please check the appropriate box to indicate whether this submission contains only paper, both paper

and electronic media, or only electronic media.

ESTABLISHMENT INFORMATION This section should include information on the locations of

all manufacturing, packaging and control sites for both drug substance and drug product. If

continuation sheets are used, please indicate where in the submission they may be found. For each

site please include the name, address, telephone number, registration number (Central File Number),

Drug Master File (DMF) number, and the name of a contact at the site. The manufacturing steps and/or type

of testing (e.g. final dosage form, stability testing) conducted at the site should also be included.

Please indicate whether the site is ready for inspection or, if not, when it will be ready. Please note

that, when applicable, the complete establishment description is requested under item 15.

CROSS REFERENCES This section should contain a list of all License Applications,

Investigational New Drug Applications (INDs), NDAs, Premarket Approval Applications (PMAs),

Premarket Notifications (510(k)s), Investigational Device Exemptions (IDEs), Biological Master

Files (BMFs) and DMFs that are referenced in the current application.

Items 1 through 20 on the reverse side of the form constitute a check list that should be used to

indicate the types of information contained within a particular submission. Please check all that

apply. The numbering of the items on the checklist is not intended to specify a particular order for

the inclusion of those sections into the submission. The applicant may include sections in any order,

but the location of those sections within the submission should be clearly indicated in the Index. It is

therefore recommended that, particularly for large submissions, the Index immediately follows the

Form FDA 356h and, if applicable, the User Fee Cover Sheet (Form FDA 3397).

The CFR references are provided for most items in order to indicate what type of information should

be submitted in each section. For further information, the applicant may consult the guidance

documents that are available from the Agency.

Signature The form must be signed and dated. Ordinarily only one person should sign the form, i.e.,

the applicant, or the applicant’s attorney, agent, or other authorized official. However, if the person

signing the application does not reside or have a place of business within the United States, the

application should be countersigned by an attorney, agent, or other authorized official who resides or

maintains a place of business within the United States.

FORM FDA 356h (3/05) Page 4 of 4